Clinical trials: COVID-19 Vaccine
COVID-19 (Healthy Volunteers)
Safety, Reactogenicity, and Immunogenicity Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510)
This is randomized, placebo-controlled, observer-blinded, multi-center study to assess safety, reactogenicity and immunogenicity of booster vaccination of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted…
- Trial name
- NCT05175950
- Testing
- SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine (GBP510) (RBD of SARS-CoV-2 25ug / dose) Adjuvanted with AS03, Normal saline
- Where
- 9 sites in South Korea
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- Korea University Guro Hospital
Healthy, Immunization; Infection
BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers
As previously shown, individuals who experienced COVID-19 have developed some protective immunity to reinfection. The magnitude and duration of protection from reinfection conferred by the infection may be weaker after an…
- Trial name
- CoviCompareP (NCT04824638)
- Testing
- 3 doses of BNT162b2 vaccine, 2 dose of BNT162b2 vaccine
- Where
- 11 sites in France
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Covid19, SARS (Severe Acute Respiratory Syndrome)
A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19
In this randomized double blind Phase 3 clinical trial we will study the efficacy and safety of oral polio vaccine with and without NA-831 versus placebo.
- Conditions
- Covid19, SARS (Severe Acute Respiratory Syndrome), SARS-CoV Infection, SARS-CoV-2
- Trial name
- OPV-NA831 (NCT04540185)
- Testing
- Biological: oral polio vaccine, NA-831, Combination of oral polio vaccine and NA-831
- Where
- 10 sites in United States, New Zealand
- Volunteers
- 3,600 people, healthy volunteers welcome
- Sponsor
- Biomed Industries, Inc.
Rheumatoid Arthritis, Autoimmune Rheumatologic Disease
COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases
People living with Systemic autoimmune rheumatic diseases (SARDs) face a new and urgent dilemma: immunosuppression increases risk for worse COVID-19 infection, yet an immune stimulation, such as vaccination, could re-activate…
- Conditions
- Rheumatoid Arthritis, Autoimmune Rheumatologic Disease, Systemic Lupus Erythematosus, Systemic Vasculitis
- Trial name
- COVBIRD (NCT05236491)
- Testing
- COVID-19 vaccine
- Where
- 2 sites in Canada
- Volunteers
- 287 people
- Sponsor
- Paul R Fortin
COVID-19
Phase Ⅰ Clinical Trial of a Candidate COVID-19 Vaccine
In this trial, a single-arm, open-label study design will be used to evaluate the safety and tolerability after vaccination with escalating doses of the investigational vaccine (Recombinant COVID-19 Vaccine (chimpanzee adenovirus…
- Trial name
- NCT05706324
- Testing
- Recombinant COVID-19 Vaccine (chimpanzee adenovirus vector) for Inhalation
- Where
- Singapore
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Wuhan BravoVax Co., Ltd.
COVID-19, Vaccine Adverse Reaction
Adverse Events Report of Inactivated COVID-19 Vaccine
Numerous vaccination studies are conducted to protect against COVID-19 infection, and preclinical and clinical studies are still ongoing worldwide.
- Trial name
- NCT05026879
- Testing
- Inactivated COVID-19 vaccine (CoronaVac)
- Where
- Turkey (Türkiye)
- Volunteers
- 4,040 people, healthy volunteers welcome
- Sponsor
- Bozyaka Training and Research Hospital
SARS-CoV-2
A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)
This trial is a phase II clinical trial of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021). The trial was randomized, blinded, placebo controlled.
- Trial name
- NCT05939648
- Testing
- SARS-CoV-2 Bivalent mRNA Vaccine, Saline
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
Covid19
A Immuno-bridging and Immunization Schedules Study of COVID-19 Vaccine (Vero Cell), Inactivated
This trial is a randomized study to evaluate the immunogenicity of COVID-19 Vaccine (Vero Cell), Inactivated and in population aged 60 years old and 3-17 years old with different schedules compared to that in population aged…
- Trial name
- COVID-19 (NCT04863638)
- Testing
- 3-doses schedule 1 of COVID-19 Vaccine (Vero Cell), Inactivated, 3-doses schedule 2 of COVID-19 Vaccine (Vero Cell), Inactivated, 3-doses schedule 3 of COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- China
- Volunteers
- 4,400 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Pneumonia, Influenza
ACTIVATE in Public Housing
This multilevel, multidisciplinary, theoretically based, culturally sensitive, community-engaged intervention sets out to mitigate uptake barriers and non-adherence to vaccination schedules as recommended by the CDC and increase…
- Conditions
- Pneumonia, Influenza, Varicella Zoster, Meningitis
- Trial name
- NCT06075732
- Testing
- Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Charles Drew University of Medicine and Science
COVID-19, COVID-19 Vaccine
Safety and Immunogenicity of the RNA MCTI CIMATEC HDT Vaccine
A multicenter, randomized, double-blind, active comparator, non-inferiority, multicenter IIb clinical trial to compare the safety and immunogenicity of two dose levels of the MCTI CIMATEC HDT RNA Vaccine against two authorized…
- Trial name
- NCT05542693
- Testing
- RNA MCTI CIMATEC HDT 5µg, RNA MCTI CIMATEC HDT 10µg, Covishield® - AstraZeneca
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Azidus Brasil
Bronchiolitis; Respiratory Syncytial Virus
COVID-19 Impact on RSV Emergency Presentations
Bronchiolitis is a very common winter disease that normally affects children less than one year of age. It is a common reason for parents and carers to bring their child to an Emergency Department (ED) and the frequent need for…
- Trial name
- BronchSTART (NCT04959734)
- Where
- United Kingdom
- Volunteers
- 3,000 people
- Sponsor
- University Hospitals, Leicester
COVID-19 Infection, COVID-19 VACCINE
Third Dose Vaccination With AstraZeneca or Pfizer COVID-19 Vaccine Among Adults Received Sinovac COVID-19 Vaccine
This prospective, multi-center, randomized, observer-blind Phase 2 study. A total of 1320 participants will be divided into 2 groups (660 each) receiving either full dose or half dose of either AZ or PF.
- Trial name
- NCT05049226
- Testing
- AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) full dose, Pfizer/BioNTech BNT162b2 vaccine (PF) full dose, AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) half dose
- Where
- 7 sites in Thailand
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- Mahidol University
COVID-19 Vaccine Adverse Reaction
Detoxification From the Lipid Tract
Apart from electroencephalogram biofeedback and electrical brain stimulation adopted for maintenance treatment, the study utilizes ultra-low frequency transcranial magnetic stimulation (ULF-TMS) for initial γ-aminobutyric acid…
- Trial name
- NCT06357104
- Testing
- electroencephalogram biofeedback, electrical brain stimulation, ultra-low frequency transcranial magnetic stimulation
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Pachankis, Yang I., M.D.
SARS-CoV-2 Infection
Clinical Study of the Third Dose Immunization Schedule of COVID-19 Inactivated Vaccine, (Vero Cells) in Adults Aged 18 Years and Above (6 Months After Two Doses)
To evaluate the immunogenicity and safety of the third dose SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above, who inoculated the third dose after 6 months since finished two doses schedule of…
- Trial name
- NCT05216484
- Testing
- SARS-CoV-2 Vaccine, Inactivated (Vero Cell)
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Medical Sciences
COVID-19, Vaccine Reaction
The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001
The goal of this clinical trial is to assess the immunogenicity and safety following a heterologous booster dose of recombinant SARS-CoV-2 vaccine (CHO cell) LYB001 in adults 18-59 years of age completed two- or three-dose…
- Trial name
- NCT05928455
- Testing
- LYB001, CoronaVac
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
COVID-19
A Phase 2 Trial of the Immunogenicity and Safety of CVXGA Intranasal COVID Vaccine in Healthy Adults
The purpose of this trial is to evaluate immunogenicity and safety of CVXGA administered as a single intranasal dose against SARS-CoV-2 S-protein in participants.
- Trial name
- NCT05736835
- Testing
- CVXGA
- Where
- 10 sites in United States
- Volunteers
- 227 people, healthy volunteers welcome
- Sponsor
- CyanVac LLC
COVID-19
Study of the Effectiveness of The COVID-19 Vaccine
This descriptive study examines neutralizing antibody levels against COVID-19 in health workers before and after the 2nd booster of the COVID-19 vaccine in Surakarta, Indonesia.
- Trial name
- NCT05766176
- Testing
- COVID-19 Antibody
- Where
- Indonesia
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Universitas Sebelas Maret
COVID-19 Vaccine, Breastmilk
Is COVID-19 Transmitted Through Human Milk? Implications for Breastfeeding and Human Milk Banking-Study 1c
This will be a prospective observational study of lactating mothers who are planning to, have scheduled or have received vaccination against SARS-COV-2 (COVID-19 vaccine).
- Trial name
- NCT05004740
- Testing
- Vaccinated Pregnant or Lactating persons
- Where
- Canada
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Deborah O'Connor
Post-Acute COVID-19 Vaccination Syndrome, Postviral Fatigue
Clinical Laboratory Evaluation, Assessment of Symptoms and Recovery in Patients With Post-COVID-19-Vaccination Syndrome
Some people report persistent health problems after receiving the COVID-19 vaccine. These symptoms persist well beyond typical short-term vaccine side effects and are not attributable to any other known medical conditions.
- Trial name
- CLEAR (NCT07400848)
- Testing
- Blood sampling and analysis, The continuous Reactive Hyperemia Index (InRHI) measured by EndoPAT
- Where
- Switzerland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- University of Bern
Vaccine
Double-blind, Placebo-controlled, Randomized Study of the Tolerability, Safety and Immunogenicity of an Inactivated Whole Virion Concentrated Purified Vaccine (CoviVac) Against Covid-19 of Children at the Age of 12-17 Years Inclusive"
Randomized, double-blind, placebo controlled, multi-center clinical trials of the tolerability, safety and immunogenicity of the inactivated whole-virion concentrated purified vaccine against COVID-19, manufactured by FSBSI…
- Trial name
- NCT05715918
- Testing
- Vaccine for intramuscular injection
- Where
- 4 sites in Russia
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.